SCHEMBL4595228

SCHEMBL4595228

OCC(CO)CCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.54
ANPEP P15144 2/20 0.47
ERAP1 Q9NZ08 2/20 0.47
ERAP2 Q6P179 1/20 0.47
TSHR P16473 2/20 0.46
ACP3 P15309 1/20 0.46
CNR2 P34972 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP1 P29466 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TRPA1 O75762 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
KEAP1 Q14145 1/20 0.43
CYP2A6 P11509 1/20 0.42
HTR2A P28223 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19285755 0.95 TDP1 (0.54) TDP1ANPEPERAP1ERAP2TSHR
SCHEMBL7547930 0.89 TRPA1 (0.48) TDP1ANPEPERAP1ERAP2TSHR
SCHEMBL7547922 0.89 TRPA1 (0.48) TDP1ANPEPERAP1ERAP2TSHR
SCHEMBL19824565 0.87 MMP12 (0.54) TSHRTAAR1
SCHEMBL10712129 0.86 TDP1 (0.50) TDP1ALOX15HTR2ASMN1; SMN2
SCHEMBL13765586 0.86 TDP1 (0.45) TDP1ANPEPERAP1ERAP2TSHR
SCHEMBL10488291 0.84 MMP12 (0.51) TSHRCNR2KEAP1SMN1; SMN2
SCHEMBL11274557 0.84 PPARG (0.50) TDP1ALDH1A1SMN1; SMN2TAAR1
SCHEMBL13594688 0.84 TDP1 (0.58) TDP1ANPEPERAP1ERAP2TSHR
SCHEMBL19258910 0.83 TDP1 (0.46) TDP1ALOX15HTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279518-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT TOSOH CORPORATION (JP) 2024-08-22 US disclosed
EP-4335885-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT Tosoh Corporation (JP) 2024-03-13 EP disclosed
CN-117500856-A Urethane resin-forming composition, adhesive, cured product, and method for producing cured product 东曹株式会社 2024-02-02 CN disclosed
WO-2022260107-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT 東ソー株式会社 2022-12-15 WO disclosed
US-20080318947-A1 Inhibitors of Akt Activity HEERDING DIRK A 2008-12-25 US disclosed
EP-1874768-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 EP disclosed
WO-2006113837-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318947-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 TDP1 751/4885ANPEP 2532/4885ERAP1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.